Wisconsin Alumni Research Foundation

Other

Kirk Jeffrey Hogan

Paul J Bertics

Loren C Denlinger

Kathleen Schell

James R Mickelson

Reid Spencer Alisch

David B Brunson

Andy Madrid

Monica C Roberts

Provided herein is technology for Alzheimer's disease testing and particularly, but not exclusively, methods, compositions, and related uses for detecting the presence of Alzheimer's disease.

Test for detecting Alzheimer's disease

A method of assaying nucleotide receptor P2Xpore activity in white blood cells contained within a mixed cell sample is provided comprising labeling white blood cells with a white blood cell-specific label; depolarizing the labeled white blood cells with an isotonic depolarizing solution; contacting the labeled white blood cells with dye and a P2Xagonist in an amount sufficient to activate P2Xpore activity; contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate P2Xpore activity; and analyzing dye uptake whereby P2Xpore activity is quantified by the amount of dye taken up in labeled white blood cells treated with the P2Xagonist relative to labeled white blood cells in the absence of said P2Xagonist, said P2Xpore activity being corrected for sample age and by subtraction of P2Xpore activity contributed by nonviable white blood cells.

Functional genomic pore assay for mixed cell populations

A method of rapidly assaying nucleotide receptor P2Xpore activity in white blood cells contained within a blood sample. A method according to the invention includes the steps of: (a) labeling the white blood cells with a white blood cell-specific label; (b) depolarizing the labeled white blood cells with an isotonic depolarizing solution; (c) contacting the labeled white blood cells with a dye and a P2Xagonist in an amount sufficient to activate nucleotide receptor P2Xpore activity; (d) contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate nucleotide receptor P2Xpore activity; and (e) analyzing dye uptake in labeled white blood cells whereby nucleotide receptor P2Xpore activity is quantified by the amount of dye taken up in labeled white blood cells treated with P2Xagonist relative to labeled white blood cells in the absence of P2Xagonist.

White blood cell functional assay

A method of determining whether a canine is susceptible to canine malignant hyperthermia is disclosed. In one embodiment, this method comprises the step of obtaining a nucleic acid sample from a canine and examining the DNA sample for the presence or absence of a T1640C mutation, wherein the presence of the mutation indicates that the canine is susceptible to canine malignant hyperthermia.

Growing community of inventors

Madison, WI, United States of America

Kirk Jeffrey Hogan